The Europe proton therapy market size surpassed USD 340 billion in 2025 and is predicted to reach around USD 1065.45 billion by 2035, registering a CAGR of 12.1% from 2026 to 2035. The market growth is fueled by rising cancer prevalence and demand for advanced treatment.

Europe Proton Therapy Market Statical Scope

The European proton therapy market is growing due to increasing demand for advanced cancer treatment that minimize radiation exposure in sensitive organs and pediatric cases. Countries such as Germany, the United Kingdom, France, and Italy are increasing the adoption of advanced proton systems to improve treatment precision and long-term patient safety.

The European healthcare system is focusing on improvement in precision medicine, and academic institutions and medical firms are working together on clinical trials to expand proton therapy applications. The region has regulatory support and favourable reimbursement frameworks, which further accelerate market expansion.

Europe Proton Therapy Market Share, By Procedure, 2025 (%)

• Services - Services lead the segment, with a share of 30%, driven by covering crucial functions such as installation, maintenance, and operational support, which are vital for ensuring that proton therapy systems function optimally in clinical settings.
• Beam Delivery (Pencil Beam Scanning, Passive Scattering, Uniform Scanning) - Beam Delivery (Pencil Beam Scanning, Passive Scattering, Uniform Scanning) hold a significant portion, with a share of 25%, because beam delivery methods are essential for delivering precise proton therapy that targets tumours with minimal damage to surrounding healthy tissues.

Europe Proton Therapy Market Share, By Components, 2025 (%)

• H-Minus Synchrotrons - H-Minus Synchrotrons lead the segment, with a share of 25%, providing lower-cost options for smaller proton therapy systems that still require efficient proton acceleration.
• Synchrotrons - Synchrotrons hold a significant portion, with a share of 20%, offering higher energy protons, for more precise treatments in clinical settings, making them an integral part of modern proton therapy systems.

Europe Proton Therapy Market Share, By Type, 2025 (%)

• Rotating Proton Therapy Systems - Rotating Proton Therapy Systems dominate with 60% of the market share, because of their greater flexibility and precision in delivering proton therapy from various angles, which is crucial for treating complex and irregular tumours.
• Non-Rotating Proton Therapy Systems - Non-Rotating Proton Therapy Systems hold a significant portion, with a share of 40%, because of cost-effectiveness and a simpler alternative for proton therapy, but lack the same flexibility and precision compared to rotating systems.

Europe Proton Therapy Market Share, By Set-Up Systems, 2025 (%)

• Multi-Room Systems - Multi-Room Systems dominate with 70% of the market, driven by high patient volume and the ability to treat multiple patients simultaneously, which makes them ideal for larger clinics and hospitals with high patient volumes.
• Single-Room Systems - Single-Room Systems hold a significant portion, with a share of 30%, because they offer a compact and cost-efficient solution for smaller or specialized facilities with limited space and fewer patients.

Europe Proton Therapy Market Share, By Applications, 2025 (%)

• Lung Cancer - Lung Cancer holds a significant portion, with a share of 25%, supported by proton therapy's ability to deliver highly targeted treatment, minimizing damage to lung tissue and adjacent structures such as the heart.
• Prostate Cancer - Prostate Cancer dominates with 30% of the market, driven by proton therapy's precision in delivering radiation directly to prostate tumours with minimal damage to surrounding organs such as the bladder and rectum.

Europe Proton Therapy Market Share, By End Use, 2025 (%)

• Hospitals - Hospitals dominate with 50% of the market share, driven by high patient volume, large infrastructure and the capacity to support the complex systems required for proton treatment.
• Ambulatory Surgical Centres - Ambulatory Surgical Centres hold a significant portion, with a share of 30%, supported by outpatient treatment trends and the gradual integration of compact radiology solutions in cancer care.

Competitive Landscape

Key players in the proton therapy market include Varian, IBA (Ion Beam Applications), Hitachi, ProNova Solutions, Mitsubishi Electric, Sumitomo Heavy Industries, ProTom International, and Optivus Proton Therapy. Varian is dominating the market by offering advanced treatment solutions. Mevion Medical Systems is an expert in providing compact, single-room proton therapy systems (SART). Companies are contributing to the market by enhancing the accessibility and affordability of proton therapy.

Recent Developments in the Market

In May 2026, Mevion Medical Systems introduced the MEVION S250-FIT, the first proton therapy system designed to fit within a LINAC vault. This system has successfully gained U.S. FDA clearance with CE- marking.

Segments Covered in the Report

By Procedure

• Accelerators (Cyclotrons, Synchrotrons)
• Beam Delivery (Pencil Beam Scanning, Passive Scattering, Uniform Scanning)
• Modulators
• Software
• Services

By Components

• Proton Accelerator
• Cyclotrons
• Synchrotrons
• Synchrocyclotrons
• Linacs
• H-Minus Synchrotrons
• Separated Sector Cyclotrons

By Type

• Rotating Proton Therapy Systems
• Non-Rotating Proton Therapy Systems

By Set-Up Systems

• Multi-Room Systems
  Single-Room Systems

By Applications

• Pediatric Cancer
• Prostate Cancer
• Head and Neck Cancer
• Breast Cancer
• Lung Cancer

By End Use

• Hospitals
• Cancer Research Institutes
• Ambulatory Surgical Centres